ARS Pharmaceuticals (SPRY) Other Non Operating Income (2022 - 2026)
ARS Pharmaceuticals (SPRY) posted Other Non Operating Income of $2.0 million for Q1 2026, up 124.58% sequentially from -$8.0 million in Q4 2025, and down 39.2% YoY from $3.2 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Other Non Operating Income (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Other Non Operating Income for 5 years, with the latest figure at $2.0 million in Q1 2026.
- Quarterly Other Non Operating Income fell 39.2% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 110.83% YoY) and the FY2025 annual result came in at $1000.0, down 99.99% from the prior year.
- Other Non Operating Income improved to $2.0 million in Q1 2026 per SPRY's latest filing, from -$8.0 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $3.8 million in Q1 2023 and troughed at -$8.9 million in Q4 2023.
- A 5-year average of $911235.3 and a median of $2.6 million in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 6521.28% in 2023, down 872.79% in 2023.
- Over 5 years, Other Non Operating Income stood at $1.2 million in 2022, then tumbled by 872.79% to -$8.9 million in 2023, then surged by 133.92% to $3.0 million in 2024, then tumbled by 364.73% to -$8.0 million in 2025, then surged by 124.58% to $2.0 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $2.0 million, -$8.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.97 Mn |
| Dec 31, 2025 | -8.01 Mn |
| Sep 30, 2025 | 2.04 Mn |
| Jun 30, 2025 | 2.73 Mn |
| Mar 31, 2025 | 3.24 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Sep 30, 2024 | 2.62 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Dec 31, 2023 | -8.92 Mn |
| Sep 30, 2023 | 3.11 Mn |
| Jun 30, 2023 | 3.23 Mn |
| Mar 31, 2023 | 3.75 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 47,000.00 |
| Jun 30, 2022 | -76,000.00 |
| Mar 31, 2022 | -151,000.00 |